Executive summary: U.S. Patent 11,827,646 covers use-based methods for treating spinal muscular atrophy (SMA) in humans by administering a therapeutically effective amount of a claimed agent (and/or a pharmaceutical composition containing that agent plus excipients), with claim scope keyed to SMA disease type (Type 0–Type 4) and patient age bracket (infant, toddler, child, adult) and, for composition claims, an oral solution administration mode. The enforceable “center of gravity” is therefore method-of-treatment and method-of-administration claim coverage, not molecular structure. This patent’s practical value for licensing, generic risk, or design-around depends on whether an accused product’s labeling and regimen match the claim language: SMA type and age, and oral solution formulation.
What is the scope of US Patent 11,827,646 claims for SMA treatment methods?
Short answer: The patent’s claims are method-of-treatment and method-of-administration claims for SMA using a therapeutically effective amount of an unspecified active (the active and salt are referenced as “or a pharmaceutically acceptable salt thereof”), including composition-based claims for an oral solution and excipient-containing formulations.
Claim architecture: method claims vs composition claims
From the claim set provided, the patent splits into two functional groupings:
-
Bare method-of-treatment (administering an active or a salt)
- Claim 1: administer a therapeutically effective amount of the claimed active ingredient (or a pharmaceutically acceptable salt).
- Claims 2–6: same method limited by SMA type (Type 0, 1, 2, 3, 4).
- Claims 7–10: same method limited by patient age group (infant, toddler, child, adult).
-
Composition-containing method claims (administering a formulation with excipients)
- Claim 12: method using a pharmaceutical composition comprising the active (or salt) and one or more pharmaceutically acceptable excipients.
- Claims 13–17: composition method limited by SMA type.
- Claims 18–21: composition method limited by patient age group.
- Claims 22 and 24: composition administered as an oral solution (Claim 22 is tied to Claim 12’s framework; Claim 24 is a similar oral-solution limitation tied to Claim 23’s broader excipient composition clause).
- Claims 11, 23: appear to be truncated in the excerpt (“administering … a therapeutically effective amount of” in claim 11; and “comprising and one or more … excipients” in claim 23). The structure indicates they are also composition/method variants, but the active identity is not shown in the excerpt you provided.
SMA disease-type specificity: how the claims narrow
The claims explicitly cover Type 0 through Type 4 SMA. That matters for both infringement mapping and carve-outs:
- If the accused product is prescribed only for a subset (for example, only Type 1 and Type 2), the patentee would target only the corresponding narrower claims, not the full set.
- If the product label or supported regimen includes treatment for multiple SMA types, the patentee can pick and choose the strongest matching dependent claims.
Patient age specificity: how the claims may track real-world labeling
Age limitations appear in dependent form:
- Infant (Claim 7 / Claim 18)
- Toddler (Claim 8 / Claim 19)
- Child (Claim 9 / Claim 20)
- Adult (Claim 10 / Claim 21)
In practice, infringement in method-of-treatment claims often tracks the indications and patient populations that are explicitly taught by the label or promotional materials. If clinical use is broader than label, the patentee still may argue induced infringement via off-label use, but enforcement strategy typically prioritizes congruence with approved indications.
Route/formulation specificity: oral solution as a key narrowing element
The oral solution limitation is explicit for composition claims:
- Oral solution tied to the excipient-containing composition frame (Claim 22 and Claim 24).
This creates a clean technical fork for design-around and invalidity/feature-existence analyses:
- An accused product in a different dosage form (for example, oral suspension, granules, film-coated tablets, intrathecal, IV) can argue non-infringement against the oral-solution dependent claims.
- If the independent composition claims (12, 23) do not require oral solution, route differences may still permit infringement under the broader composition method framework if the excipient-containing composition is administered at a therapeutically effective amount to treat SMA.
How broad are the independent claim positions compared to the dependent claims?
Independent-ish breadth in Claim 1 and Claim 12
- Claim 1: covers treatment for “spinal muscular atrophy in a human in need thereof” via administering a therapeutically effective amount of the active (or salt). No SMA type or age is required.
- Claim 12: similarly broad but requires a pharmaceutical composition with excipients.
Net effect: Dependent claims primarily add scope fences (SMA type, age, oral solution). The “center” of claim coverage sits in:
- Active administration for SMA (Claim 1)
- Excipient-containing pharmaceutical composition administration for SMA (Claim 12)
with the other claims acting as narrower hooks for specific populations and dosing modalities.
Dependent claims create multiple infringement “entry points”
For enforcement or licensing:
- Claim 1 and Claim 12 support broad coverage across SMA types and age groups.
- Dependent claims provide redundancy. Even if an accused regimen is disputed for one population, it may match another.
What patents protect SMA oral-solution method of treatment claims in the US?
Short answer: You have only provided the claim text for U.S. 11,827,646, not the patent family details (assignee, title, priority dates), the specification’s agent identity, or the cited references. Without those bibliographic elements, a complete “landscape” across US SMA method-of-treatment patents cannot be produced accurately.
Patent claim scope: what exactly is required to infringe?
Based on the claim language provided, a practitioner-level infringement checklist for US 11,827,646 looks like this:
Core elements for Claim 1
- A human in need of treatment for SMA
- Administering to the human
- A therapeutically effective amount of:
- the claimed active (not shown in your excerpt), or
- a pharmaceutically acceptable salt thereof
Additional elements for dependent claims
- SMA type constraint (Claims 2–6)
- Age group constraint (Claims 7–10)
- For composition claims (Claims 12–24), the administration is of:
- a pharmaceutical composition comprising the active (or salt) and one or more pharmaceutically acceptable excipients
- For oral solution dependent claims (Claims 22 and 24):
- the composition is administered as an oral solution
Practical evidence sources
In enforcement, the strongest proof typically comes from:
- FDA label indications and patient populations (SMA types, age groups)
- prescribing information and route/formulation language
- promotional materials tying regimen to “therapeutically effective amount” for SMA
- product composition dossiers confirming excipient inclusion (composition claims)
- product dosage form confirmations confirming “oral solution” status
What is the enforceable “variant map” inside this patent?
Below is a structured “variant map” of claim limitations that typically guides freedom-to-operate and licensing scope.
| Claim cluster |
Required limitation(s) |
Enforcement leverage |
| Claim 1 |
Treat SMA by administering active/salt at therapeutic effective amount |
Broadest method-of-treatment hook |
| Claims 2–6 |
Claim 1 plus SMA Type 0–4 |
Narrow, label-aligned hooks |
| Claims 7–10 |
Claim 1 plus patient age bracket (infant to adult) |
Population-specific hooks |
| Claim 12 |
Treat SMA by administering excipient-containing composition with active/salt |
Route-agnostic composition hook (no oral solution required) |
| Claims 13–17 |
Claim 12 plus SMA Type 0–4 |
Indication-granular hooks |
| Claims 18–21 |
Claim 12 plus age bracket |
Pediatric label-aligned hooks |
| Claim 22 |
Claim 12 plus oral solution |
Route/dosage-form hook |
| Claim 23 |
Method with composition including excipients (truncated excerpt) |
Another composition variant |
| Claim 24 |
Claim 23 plus oral solution |
Route/dosage-form hook (redundancy) |
When does this patent lose exclusivity or expire?
No expiration timeline can be computed from the excerpt because the filing date, priority date(s), patent term adjustments, and maintenance status are not provided.
What Orange Book status applies to US 11,827,646?
A definitive Orange Book listing cannot be produced from the excerpt because Orange Book association requires the FDA application/active ingredient and the patent-to-product linkage, which are not included.
How strong are method-of-use claims like these for SMA licensing and litigation?
Strength drivers intrinsic to the claim set you provided
- Direct “administering” language: ties to the act of treatment, not merely composition possession.
- Therapeutically effective amount: broad enough to cover a range of dosing regimens so long as efficacy is established.
- Independent coverage without added limits (Claims 1 and 12): the dependent claims add specific niches but do not remove the broader baseline.
- SMA disease type and age are enumerated: creates multiple matchable dependent claims for label-aligned populations.
Strength reducers common to method claims (still grounded in your provided language)
- Active ingredient identity is not visible in your excerpt: without the specification identity, it is impossible to map the patent to a known marketed agent and thus to evaluate actual competitive overlap.
- Oral solution restriction is only in dependent claims: a competing dosage form can avoid the oral solution dependent coverage while still potentially falling under the broader composition method claims if excipient-containing composition is administered for SMA.
- “Human in need thereof” is fact-and-regimen dependent: infringement evidence often requires proof that the administered product was used to treat SMA, not merely manufactured.
Which generic or biosimilar entry risks exist for SMA method-of-treatment patents like this?
A generic “Paragraph IV” risk analysis cannot be completed from the excerpt because it requires:
- the FDA NDA/BLA linkage and Orange Book patent list,
- the generic applicant’s proposed product label and route/dosage form,
- and whether the applicant seeks to carve out SMA types, age groups, or dosing forms.
How do formulation and route choices affect design-around for this patent?
Even without knowing the active identity, the claim structure indicates route and formulation strategies that typically matter:
Oral solution vs other oral dosage forms
- If a product is not an oral solution, it may still infringe Claims 1 and 12 if it uses the same active/salt and is administered for SMA.
- It may avoid Claims 22 and 24 if those dependents are the only hooks for oral-solution-specific infringement.
Excipient inclusion
- Claims 12–24 require a “pharmaceutical composition” with excipients.
- A product delivered without qualifying “pharmaceutically acceptable excipients” as claimed would argue non-infringement against those composition-based claims, but Claim 1 can still capture pure active/salt administration.
Patient subpopulation carve-outs
- Dependent claims include Type 0–4 and age brackets. A competitor’s label that excludes certain populations may weaken or narrow enforcement to only the included types and ages.
Key Takeaways
- U.S. 11,827,646 is built around method-of-treatment (Claims 1–10) and method-of-treatment using an excipient-containing composition (Claims 12–24) for SMA.
- The patent’s most operationally significant limitations are: SMA Types 0–4, patient age bracket, and for dependent composition claims, administration as an oral solution (Claims 22 and 24).
- The claim structure provides layered infringement hooks: broad independent claims (1, 12) plus narrower, label-aligned dependent claims (types, ages, oral solution).
- A full patent landscape for SMA in the US, including Orange Book status, expiration timelines, and competitor infringement risk, cannot be generated from the claim text alone because the patent’s bibliographic record and the related FDA product linkage are not included.
FAQs
-
Do dependent claims in U.S. 11,827,646 require proving the same dosing amount each time?
They all hinge on “therapeutically effective amount”; the dependent limitations add population or formulation features, not a different dosing standard.
-
If a product treats SMA types other than 0–4, does U.S. 11,827,646 still apply?
The claims expressly list SMA Type 0–4 in dependent form; Claim 1 and Claim 12 do not require the type limitation, so coverage is anchored to “spinal muscular atrophy” as such.
-
Can an oral tablet avoid the oral-solution dependent claims?
It can avoid Claims 22 and 24 because they specify “oral solution,” but it may still be within Claims 1 and 12 if the active/salt and excipient composition elements align.
-
Does U.S. 11,827,646 cover both method of treatment and method of administration?
Yes. The claims are drafted as methods comprising “administering” the active or composition to a human for SMA.
-
What is the fastest claim to target in licensing negotiations for SMA?
The broadest independent anchors are Claim 1 (active/salt administration) and Claim 12 (excipient-containing composition administration), with oral-solution and population-specific dependent claims as additional leverage.
References
No sources cited.
